α meca32 (Novus Biologicals)
Novus Biologicals is a verified supplier 
Novus Biologicals manufactures this product 
93
Structured Review
Novus Biologicals
α meca32
α Meca32, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α meca32/product/Novus Biologicals
Average 93 stars, based on 30 article reviews
α Meca32, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α meca32/product/Novus Biologicals
Average 93 stars, based on 30 article reviews
α meca32 - by Bioz Stars,
2026-03
93/100 stars
Images
1) Product Images from "PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors"
Article Title: PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Journal: Clinical Cancer Research
doi: 10.1158/1078-0432.CCR-23-1182
Figure Legend Snippet: HC-5404 sensitizes 786-O xenografts to the antiangiogenic effects of axitinib. A, IHC images of 786-O xenograft sections stained with antibodies specific to Meca32, CD31, and SMA. Scale bar = 150 μm. HC-5404 and axitinib administered at 30 mg/kg, twice-a-day for 7 days. B–D, Quantification of IHC staining of xenograft sections. Graphs indicate proportion of cells stained positive for Meca32, positive for CD31 in absence of SMA (%CD31 + SMA − ), or cells that stain positive for both CD31 and SMA (%CD31 + SMA + ). One-way ANOVA statistical analysis evaluated differences between treatment groups; asterisks indicate significant differences (*, P < 0.05; **, P < 0.01; ****, P < 0.001).
Techniques Used: Staining, Immunohistochemistry
Figure Legend Snippet: Addition of HC-5404 to axitinib regimen induces tumor regression. A, 786-O tumor growth across the study period. Xenografts that progressed in presence of axitinib for 14 days were rerandomized and transferred to indicated treatment groups for an additional 28 days. Data represent mean ± S.E.M. Final tumor volume analyzed by Welch ANOVA. Data represent mean ± S.E.M., n = 8 mice per group (**, P < 0.01; ***, P < 0.005; ****, P < 0.001). B, IHC images of xenograft sections stained with antibodies specific for CD31 and SMA. C, Quantification of proportion of cells that stained positive for Meca32, CD31+SMA- (immature blood vessels), or CD31 + SMA + (mature blood vessels) in B . One-way ANOVA was used to evaluate the statistical significance between groups. Asterisks indicate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001). D, Quantification of IHC staining of tumor sections using antibodies specific for the pericyte markers NG2 and MCAM. One-way ANOVA statistical analysis evaluated differences between treatment groups; asterisks indicate significant differences (**, P < 0.01; ***, P < 0.005; ****, P < 0.001).
Techniques Used: Staining, Immunohistochemistry